RNA-based therapies, such as siRNA, mRNA, and ASOs, have emerged as groundbreaking treatments for genetic disorders, cancers, and infectious diseases. However, the delivery challenge remains a major barrier—naked RNA molecules are highly unstable, easily degraded by nucleases, and have poor cellular uptake. Litchlab’s advanced liposomal drug delivery platform offers an innovative solution, enhancing RNA stability, targeting efficiency, and therapeutic efficacy.  

Why Liposomes Are Critical for RNA Drug Delivery  

Liposomes serve as highly effective carriers for RNA-based therapeutics due to their unique advantages:  

Encapsulation & Protection: Liposomes form a protective lipid bilayer around RNA molecules, preventing degradation by serum nucleases and improving systemic circulation time.  

Enhanced Cellular Uptake: By mimicking biological membranes, liposomes facilitate endocytosis and intracellular delivery of RNA, overcoming the natural barriers of cell membranes.  

Targeted Delivery: Litchlab employs surface modifications, such as PEGylation and ligand attachment (antibodies, peptides, aptamers), enabling RNA therapeutics to reach specific cells or tissues while reducing off-target effects.  

Controlled Release: Stimuli-responsive liposomes (pH-sensitive, enzyme-triggered) ensure precise and sustained RNA release, improving bioavailability and therapeutic outcomes.  

Litchlab’s Liposomal RNA Delivery Solutions  

siRNA Delivery for Gene Silencing  

Litchlab’s lipid nanoparticles (LNPs) and targeted liposomes efficiently encapsulate siRNA, protecting it from degradation and delivering it to the cytoplasm for effective gene silencing. This is particularly valuable in oncology and rare genetic disorders, where gene suppression can halt disease progression.  

mRNA-Based Vaccines & Therapeutics  

For mRNA delivery, Litchlab’s ionizable lipid-based liposomes protect the fragile mRNA structure and enhance endosomal escape, ensuring efficient protein translation. This technology underpins next-generation mRNA vaccines, cancer immunotherapies, and protein replacement therapies.  

ASO & RNA Editing Therapy  

Litchlab’s lipid formulations enhance the intracellular delivery of antisense oligonucleotides (ASOs) and CRISPR-based RNA therapies, offering solutions for neurological diseases, muscular disorders, and metabolic syndromes.  

Comprehensive Support: From Development to Manufacturing  

GMP-Grade Lipid & Liposome Production

High-purity PEGylated lipids, ionizable lipids, and cationic lipids for large-scale RNA drug formulation.  

Custom RNA-Liposome Formulation Design  

Optimized lipid ratios, charge properties, and targeting strategies for precise RNA drug delivery.  

Comprehensive Clinical & Regulatory Support  

In vivo safety, PK, and biodistribution studies to accelerate RNA drug commercialization.  

Litchlab: Pioneering the Future of RNA Drug Delivery  

By integrating state-of-the-art liposomal and RNA delivery technologies, Litchlab is shaping the next generation of RNA-based therapies. Whether in gene silencing, mRNA vaccines, or precision medicine, our lipid-based platforms are driving breakthroughs that will transform healthcare.  

For more information, please feel free to contact us at:  

E-Mail:RD2@Litchlab.com